RxDoctor Payments Data

Ian Stines, MD

Vascular Surgery · Bowling Green, KYNPI 1952711665

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (57.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 69.8% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2022 at $7,450 and has fallen 88.1% since, to $888 in 2025.

$17,417in general payments, 2019–2025

Across 99 payments — averaging $175.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$12K
  • W. L. Gore & Associates, Inc.$2K
  • Penumbra, Inc.$1K
  • Boston Scientific$508
  • Cook Medical LLC$466
  • Endologix LLC$351
  • plus $669 from 10 others

What the payments were for

  • Grants$10,00057%
  • Travel & lodging$7845%
  • Food & beverage$6,19736%
  • Education$4363%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,417 in reported general payments places this provider in the 70th percentile of 72 vascular surgery providers in Kentucky.

See all vascular surgery providers in Kentucky

Medicare billing

Part B allowed, 2024
$106,668
Medicare patients
233
Services billed
690

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban15$9,314
XareltoRivaroxaban11$5,978
Cilostazol33$685
ClopidogrelClopidogrel Bisulfate63$412
Oxycodone Hcl23$147
Pentoxifylline16$144
Atorvastatin Calcium37$110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$26$5,97811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 72 vascular surgery providers in Kentucky.

Other vascular surgery in Bowling Green

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →